Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tarlatamab + sacituzumab govitecan
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Tarlatamab + sacituzumab govitecan is a combination therapy being investigated for the treatment of neuroendocrine-derived malignancies. Tarlatamab is a bispecific T-cell engager (BiTE) that binds to delta-like ligand 3 (DLL3) on tumor cells and CD3 on T cells, facilitating the formation of an immunological synapse and subsequent T-cell mediated lysis of the cancer cells. Sacituzumab govitecan is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody targeting tumor-associated calcium signal transducer 2 (TROP2) conjugated to SN-38, a potent topoisomerase I inhibitor. This combination is currently being evaluated in a Phase I/II clinical trial sponsored by the National Cancer Institute (NCI) for patients with previously treated extensive-stage small cell lung cancer (SCLC) and extrapulmonary neuroendocrine cancer (EP-NEC).
- Brand names
- ImdelltraTrodelvy
- Other names
- AMG-757AMG757AMG 757IMMU132IMMU-132IMMU 132hRS7-SN38hRS-7-SN38hRS 7-SN38tarlatamab-dllesacituzumab govitecan-hziy
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on tarlatamab + sacituzumab govitecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tarlatamab + sacituzumab govitecan.